May 11, 2026

Idan Elmelech

Re: Employment Agreement and Executive Severance Plan Participation Agreement

Dear Idan:

This agreement confirms the terms of your employment as Chief Operating Officer of the Company commencing as of the Effective Date (as defined below). If executed, this Employment Agreement and Executive Severance Plan Participation Agreement (the “Agreement”) shall become effective retroactively as of April 20, 2026 (the “Effective Date”). Except with respect to the Equity Documents, the Restrictive Covenants Agreement (as defined below) and the Severance Plan (each as defined below), this Agreement supersedes in all respects all prior agreements between you and BridgeBio Oncology Therapeutics, Inc. (the “Company”) (or its predecessor(s)) regarding the subject matter herein, including without limitation (i) the Offer Letter, dated April 16, 2024, by and between you and the Company (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.

1.

…

May 11, 2026

Dr. Pedro Beltran

Re: Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement

Dear Pedro:

This agreement confirms the terms of your employment as Chief Executive Officer of the Company commencing as of the Effective Date (as defined below). If executed, this Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement (the “Agreement”) shall become effective retroactively as of April 20, 2026 (the “Effective Date”). Except with respect to the Equity Documents, the Restrictive Covenants Agreement (as defined below) and the Severance Plan (each as defined below), this Agreement supersedes in all respects all prior agreements between you and BridgeBio Oncology Therapeutics, Inc. (the “Company”) (or its predecessor(s)) regarding the subject matter herein, including without limitation (i) the Employment Agreement, dated August 11, 2025, by and between you and the Company (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.

1.

…

AMENDMENT NO. 9

TO TRANSITION SERVICES AGREEMENT

This Amendment No. 9 (“Amendment No. 9”) to the Agreement (as defined below) is entered into as of June 23, 2026 (the “Effective Date”) by and among BridgeBio Services Inc., a Delaware corporation (“BBIO”), TheRas, Inc., a Delaware corporation (“BBOT”), BridgeBio Pharma LLC (“BBP LLC”), and BridgeBio Oncology Therapeutics, Inc. (“PubCo”). BBIO, BBOT, BBP LLC and PubCo may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement (as defined below) to the extent defined therein.

WHEREAS, BBIO and BBOT entered into that certain Transition Services Agreement, dated April 30, 2024, as amended (the “Agreement”);

WHEREAS, the Parties now wish to further amend the Agreement to update the Service Schedule on Exhibit A thereto;

NOW, THEREFORE, in consideration of the covenants, conditions and undertakings hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.

Amendment to Service Schedule. Exhibit A of the Agreement is hereby deleted in its entirety and replaced with the following new Exhibit A attached hereto.

2.

…

IMMUNOME, INC

2024 INDUCEMENT PLAN

EFFECTIVE AS OF: OCTOBER 3, 2024

AMENDED BY THE COMPENSATION COMMITTEE AS OF: MAY 8, 2025 and MAY 12, 2026

1. GENERAL.

(a) Eligible Award Recipients.The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a bona fide period of non-employment. Persons eligible to receive grants of Awards under this Plan are referred to in this Plan as “Eligible Employees.” These Awards must be approved by either a majority of the Company’s “Independent Directors” (as such term is defined in Nasdaq Marketplace Rule 5605(a)(2)) (“Independent Directors”) or the Company’s compensation committee, provided such committee is comprised solely of Independent Directors (the “Independent Compensation Committee”) in order to comply with the exemption from the stockholder approval requirement for “inducement grants” provided under Rule 5635(c)(4) of the Nasdaq Marketplace Rules. Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 (together with any analogous rules or guidance effective after the date hereof) are referred to in this Plan as the “Inducement Award Rules.”

…

Exhibit 10.7

ENERGY VAULT HOLDINGS, INC.
2022 EQUITY INCENTIVE PLAN
NOTICE OF STOCK OPTION GRANT

You have been granted the following option to purchase shares of the Common Stock of Energy Vault Holdings, Inc. (the “Company”) on the terms and conditions set out below:

Name of Optionee:    [______]

Total Number of Shares:    [______]

Type of Option (U.S. Tax Status):    [Incentive Stock Option][Nonstatutory Stock Option]

Exercise Price per Share:    [______]

Date of Grant:    [______]

Vesting Commencement Date:    [______]

Vesting Schedule:    [To be specified in the individual award agreements]

Expiration Date:    [______]. This option expires earlier if your Service terminates earlier, as described in the Stock Option Agreement, and may terminate earlier in connection with certain corporate transactions as described in Article 9 of the Plan.

You and the Company agree that this option is granted under and governed by the terms and conditions of the Company’s 2022 Equity Incentive Plan, as the same may be amended from time to time (the “Plan”) and the Stock Option Agreement (including, if applicable, the Appendix for Non-U.S. Participants), both of which are attached to, and made a part of, this document. Capitalized terms not otherwise defined herein shall have the meanings assigned to such terms in the Plan.

…

July 13, 2026

Nitin Dahiya

48 Bedford Road

Summit, NJ 07901

n2dahiya@gmail.com

Re:Offer and Terms of Employment

Dear Nitin,

It gives me great pleasure to offer you the position of Chief Financial Officer for Energy Vault Holdings, Inc. (the “Company”). If you accept this offer, the terms and conditions of this offer letter agreement (the “Agreement”), in addition to the attachments enclosed with this Agreement, will apply to your at-will employment with the Company:

1.Start Date and Duties. If you accept this offer, and contingent on the other conditions set forth herein, your first day of employment will be 27 July, 2026. You will report to Robert A. Piconi, Chairman, Co-Founder & Chief Executive Officer. You shall perform duties consistent with your position in a professional and competent manner, and throughout your employment with the Company devote your time to such matters as the Company may reasonably require. You shall use your best efforts to complete all assignments and adhere to the Company’s procedures and policies in effect.

2.Compensation. Your gross annual base salary will be $435,000 USD, subject to standard withholdings and authorized deductions (“Base Salary”), and payable on a bi-weekly basis in accordance with the Company’s normal payroll practices. By virtue of your duties, responsibilities, and compensation, your role is an exempt position, meaning you are not eligible for overtime compensation. Your salary is subject to modification during your employment in accordance with the Company’s practices, policies, or procedures.

…

CALISTOGA RESILIENCY CENTER, LLC

4360 Park Terrace Drive, Suite 100
Westlake Village, CA 91361

					New York, New York August 4, 2025
Re:    Amendment No. 1 to the Note Purchase Agreement
TO EACH OF THE NOTEHOLDERS NAMED ON THE SIGNATURE PAGES HEREOF

Ladies and Gentlemen:

…

DMS_US.374368937.12 124054739.9 LEASE AGREEMENT BETWEEN 184 PROPERTY OWNER, LLC, a New Jersey limited liability company, LANDLORD, -AND- AQUESTIVE THERAPEUTICS, INC., a Delaware corporation, TENANT DATED: , 2026

---

TABLE OF CONTENTS Page -i- ARTICLE 1 DEFINITIONS ................................................................................................. 4 ARTICLE 2 DEMISE, TERM.............................................................................................. 5 ARTICLE 3 BASIC RENT; ADDITIONAL RENT ............................................................ 6 ARTICLE 4 REAL ESTATE TAXES ................................................................................. 7 ARTICLE 5 OPERATING EXPENSES ............................................................................ 10 ARTICLE 6 ELECTRICITY .............................................................................................. 12 ARTICLE 7 MAINTENANCE; ALTERATIONS; REMOVAL OF TRADE FIXTURES .................................................................................................... 13 ARTICLE 8 USE OF PREMISES ...................................................................................... 15 ARTICLE 9 LANDLORD’S SERVICES .......................................................................... 16 ARTICLE 10 COMPLIANCE WITH REQUIREMENTS .................................................. 20 ARTICLE 11 COMPLIANCE WITH ENVIRONMENTAL LAWS .................................. 21 ARTICLE 12 DISCHARGE OF LIENS

…

THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LICENSE AND SUPPLY SECOND AMENDMENT This LICENSE AND SUPPLY SECOND AMENDMENT (“Second Amendment”) is entered into as of 20 April 2026 (the “Second Amendment Effective Date”) by and between Aquestive Therapeutics, Inc., a Delaware corporation having its principal place of business at 30 Technology Drive, Warren, New Jersey 07059 (“Aquestive”), and Atnahs Pharma UK Limited, a company registered in England and Wales having its principal place of business at Sovereign House, Miles Gray Road, Basildon, Essex SS14 3FR (“Pharmanovia”). Aquestive and Pharmanovia are sometimes referred to hereinafter individually as a “Party” and collectively as the “Parties.” RECITALS: A. Aquestive and Pharmanovia entered into a License and Supply Agreement related to the Product in certain territories as specified therein on September 26, 2022, which was subsequently amended by an Amendment Agreement dated 27 March 2023 (together, the “Agreement”). B. Aquestive and Pharmanovia have agreed to enter into this Second Amendment in order to further amend certain terms of the Agreement. C. In consideration of the foregoing and the mutual representations, warranties and covenants contained herein, the Parties, intending to be legally bound hereby, agree as follows: 1. DEFINITIONS Unless otherwise defined in this Second Amendment, capitalized terms used in this Amendment have

…

SEPARATION AND GENERAL RELEASE AGREEMENT

This SEPARATION AND GENERAL RELEASE AGREEMENT (this “Agreement”) is entered into by and between Comscore, Inc., a Delaware corporation (the “Company”), and Steve Bagdasarian (“Executive”). The Company and Executive are each referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, Executive and the Company are parties to that certain Severance Agreement effective as of March 27, 2024 (the “Severance Agreement”);

WHEREAS, Executive and the Company have agreed that Executive’s employment with the Company will end on December 1, 2026, unless terminated earlier due to a termination by the Company for Cause (as defined in the Severance Agreement) or due to Executive’s resignation (the date that Executive’s employment with the Company ends, the “Separation Date”);

WHEREAS, the Company seeks to retain Executive prior to the Separation Date for the purpose of obtaining Executive’s assistance in transitioning his duties, and Executive wishes to provide such assistance;

WHEREAS, subject to the terms of this Agreement, the Parties wish for Executive to be eligible to receive certain severance payments and other benefits, which payments and benefits are conditioned upon Executive’s satisfaction of the terms of this Agreement; and

WHEREAS, the Parties wish to resolve any and all claims that Executive has or may have against the Company and any of the other Released Parties (as defined below), including any claims that Executive may have arising out of Executive’s employment or the end of such employment.

…

COMSCORE, INC.

CHANGE OF CONTROL AND SEVERANCE AGREEMENT

This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between Mary Margaret Curry (“Executive”) and comScore, Inc., a Delaware corporation (the “Company”), effective as of the date on which this Agreement has been executed by all parties hereto (the “Effective Date”).

RECITALS

1.The Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, to provide Executive with an incentive to continue his or her employment, and to motivate Executive to maximize the value of the Company for the benefit of its stockholders.

2.The Committee believes that it is imperative to provide Executive with certain severance benefits upon Executive’s termination of employment under certain circumstances. These benefits will provide Executive with enhanced financial security and incentive and encouragement to remain with the Company.

3.The Company and Executive desire to terminate the Change of Control Agreement, dated July 6, 2022, and the Severance Agreement, dated July 6, 2022, between the Company and Executive (collectively, the “Prior Agreements”) in exchange for each party’s entry into this Agreement.

4.Certain capitalized terms used in the Agreement are defined in Section 6below.

AGREEMENT

…

August 9, 2026

By E-mail

Mary Margaret Curry

Comscore, Inc.

11950 Democracy Drive

Suite 600

Reston, VA 20190

Dear Mary Margaret:

I am pleased to inform you that the Board of Directors (the “Board”) of Comscore, Inc. (the “Company”) has approved your eligibility for new equity incentive awards under the Company’s 2018 Equity and Incentive Compensation Plan (the “Plan”), subject to your agreement to the terms set forth in this letter (this “Agreement”).

Upon execution of this Agreement by you and the Company, the letter agreement, dated July 5, 2022, between you and the Company (the “2022 Letter”) will be deemed amended to reflect the following terms, which will govern your continued employment with the Company.

1.Equity Awards. As soon as practicable (and subject to terms approved by the Board and set forth in the applicable award agreement), you will receive (a) a one-time grant of options to purchase 60,000 shares of Comscore common stock under (and pursuant to the terms of) the Plan, with a per share exercise price equal to the closing price per share of Comscore common stock on the date of grant, which grant will vest in equal annual installments over four years subject to your continued service with the Company through each vesting date; and (b) a one-time grant of 60,000 restricted stock units under (and pursuant to the terms of) the Plan, which grant will vest in equal annual installments over four years subject to your continued service with the Company through each vesting date, with settlement deferred until the earlier of a separation from service or a

…